The study is a single-center, randomized, placebo-control double-blind study in frail older adults over 65yrs. to investigate the impact of Mitopure (Urolithin A) supplementation on muscle mitochondrial quality in frail older adults after 8-weeks of supplementation
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
26
UA is produced by the gut microbiome following the digestion of dietary precursors (polyphenols such as ellagitannins and punicalagins) present in fruits and nuts such as pomegranate, nuts and berries. In mouse models of aging and muscle dystrophy, UA was shown to induce mitophagy and mitochondrial function in the skeletal muscle. This was associated with improved muscle strength and endurance (Nat. Med, 2016; Sci Tran Med, 2021). In humans, UA was shown to be safe and bioavailable in multiple clinical studies (Nat. Met, 2019; Cell Rep Med, 2022; JAMA Network Open, 2022).
Placebo containing excipients other than Urolithin A (Mitopure)
McGill University Health Center
Montreal, Canada
Change in mitochondrial area between placebo and active treated groups assessed via Electron Microscopy
Time frame: 8-weeks
Change in mitochondrial cristae density between placebo and active treated groups assessed via Electron Microscopy
Time frame: 8-weeks
change between groups on the following: maximal mitochondrial O2 consumption assessed via via respirometry on permeabilized myofibers
Time frame: 8-weeks
change between groups in mitochondrial calcium retention capacity measured by mitochondrial permeability transition pore (mPTP) sensitivity to calcium
Time frame: 8-weeks
mitochondrial DNA (mtDNA) over nuclear DNA ratio (mtDNA/nDNA) via qPCR
Time frame: 8-weeks
Changes in body composition via Dual X-ray Absorptiometry (DXA) scan of total and appendicular lean mass
Time frame: 8-weeks
Changes in composition via Peripheral quantitative computed tomography (pQCT) of muscle tissue
Time frame: 8-weeks
Changes in the timed up and go test (time needed to stand from an armchair, walk a distance of 3 meters, turn around and sit back down in the chair)
Time frame: 8-weeks
Changes in grip strength measured by a hand dynamometer
Time frame: 8-weeks
Changes in Berg balance test: Participant will be asked to maintain a given position or perform a task
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 8-weeks
Changes in distance walked during the six-minute walk test
Time frame: 8-weeks
Changes in the 30-second stand test: Participant will stand as many times as s/he can from a seated position for 30-seconds.
Time frame: 8-weeks
Changes in Four-square step test: To assess balance, participant will step over small sticks placed in an X on the floor
Time frame: 8-weeks
Changes in Unipedal stance test (UPST): First a ball will be kicked to determine dominant leg, then participant will be asked to stand on one leg (barefoot) with eyes open and again with eyes closed
Time frame: 8-weeks
Recording of adverse events
Time frame: 8-weeks
Quantification of muscle fiber type (type I/II) via Myosin Heavy Chain immunolabeling
Time frame: 8-weeks
Analysis of markers of neuromuscular junction integrity (NCAM biomarker staining)
Time frame: 8-weeks
Changes in knee extension strength measured by a hand dynamometer
Time frame: 8-weeks